CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01960296
NCT01960296Phase 2Completed
CompareCT.gov

Evaluation of Clopidogrel Use in Peri-Operative General Surgery Patients: A Prospective Study

Icahn School of Medicine at Mount Sinai·interventional·Posted Oct 10, 2013·Updated May 30, 2017

In Brief

A Phase 2 clinical trial evaluating Clopidogrel and Discontinue Clopidogrel for Clopidogrel. Completed, enrolled 48 participants across 1 site.

Detailed Summary

Patients who on taking clopidogrel are randomized to either continue clopidogrel into general surgery or discontinue clopidogrel 7 days before surgery. All patients resume clopidogrel after surgery. The investigators track the development of bleeding complications that may develop within 90 days of the surgery. Patients are medically cleared to be in either arm of the study by their cardiologist and surgeon. There is currently no evidence to support for or against the use continuation or discontinuation of clopidogrel prior to general surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClopidogrel
CountriesUnited States
CollaboratorsDoris Duke Charitable Foundation

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 10, 2013
Enrollment StartJan 1, 2012
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.7 years ago

Interventions

Clopidogreldrug

Continue home dose of clopidogrel into surgery

Discontinue Clopidogreldrug

Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.